Advanced search

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
Hemeryck, Alex, C DE VRIENDT, and Frans Belpaire. 1999. “Inhibition of CYP2C9 by Selective Serotonin Reuptake Inhibitors: In Vitro Studies with Tolbutamide and (S)-warfarin Using Human Liver Microsomes.” European Journal of Clinical Pharmacology 54 (12: 947–951.
APA
Hemeryck, A., DE VRIENDT, C., & Belpaire, F. (1999). Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 54 (12, 947–951.
Vancouver
1.
Hemeryck A, DE VRIENDT C, Belpaire F. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1999;54 (12:947–51.
MLA
Hemeryck, Alex, C DE VRIENDT, and Frans Belpaire. “Inhibition of CYP2C9 by Selective Serotonin Reuptake Inhibitors: In Vitro Studies with Tolbutamide and (S)-warfarin Using Human Liver Microsomes.” EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 54 (12 (1999): 947–951. Print.
@article{115507,
  author       = {Hemeryck, Alex and DE VRIENDT, C and Belpaire, Frans},
  issn         = {0031-6970},
  journal      = {EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY},
  language     = {eng},
  pages        = {947--951},
  title        = {Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.},
  volume       = {54 (12},
  year         = {1999},
}

Web of Science
Times cited: